Post‐ <scp>FDA</scp> Approval Experience With Momelotinib in <scp>JAK</scp> Inhibitor‐Naïve Myelofibrosis: Focus on Anemia Response and Treatment‐Emergent Nephropathy and Peripheral Neuropathy
Real-world experience using momelotinib as first-line JAK2 inhibitor therapy in myelofibrosis. Anemia response was moderate (23%) while treatment-emergent adverse events included nephropathy (29%) and peripheral neuropathy (20%).
Authors
- Maymona Abdelmagid
- Rong He (ORCID: https://orcid.org/0009-0001-5611-7078)
- Animesh Dev Pardanani (ORCID: https://orcid.org/0000-0002-9084-4148)
- Yassin Bashir
- Jeanne Palmer (ORCID: https://orcid.org/0000-0002-2185-1504)
- Talha Badar (ORCID: https://orcid.org/0000-0003-1548-918X)
- Kaaren K. Reichard (ORCID: https://orcid.org/0000-0001-5439-0778)
- Aasiya Matin
- Naseema Gangat
- Cecilia Y. Arana Yi
- Hassan B. Alkhateeb
- Aref Al‐Kali
- Ayalew Tefferi
Institutions
- Mayo Clinic (US)
- Jacksonville College (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- American Journal of Hematology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1002/ajh.70203
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00